logo-loader
Proactive logo live
Recce Pharmaceuticals Ltd Recce Pharmaceuticals tackling antibiotic-resistant ‘superbugs’ with synthetic anti-infectives

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is developing new classes of synthetic...

21 hours ago
Deep dive

Race Oncology progressing a robust pipeline of clinical activities for...

Race Oncology Ltd (ASX:RAC) is advancing its Phase 2/3 cancer drug Zantrene which is a potent...

1 day, 3 hours ago
Feature

Researchers identify new pathway for acute lymphoblastic leukaemia treatment

A study led by the Walter and Eliza Hall Institute of Medical Research (WEHI) and the Peter...

5 days ago
Feature

Monash develops blood-based test for sleep deprivation with forensic potential

The Highway Patrol may soon be testing for driving impairment via sleep deprivation as well as...

6 days ago
Deep dive

Hygrovest eyes opportunities in high growth sectors

MMJ Group Holdings Ltd (ASX:MMJ) has maintained its investment strategy in 2020 with company...

6 days ago

Recce Pharmaceuticals hits major milestone in R327 clinical trial for...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham joins Proactive to talk through significant progress in the journey of RECCE® 327 (R327) for treating urinary tract infections (UTI) and urosepsis. The company has completed dosing in its Phase 1/2 clinical trial, which focused on...

21 hours ago

Join Proactive

Get ahead of the curve